Fluidigm creates and manufactures innovative technologies and life-science tools designed to revolutionize biology through a relentless pursuit of scientific truth. Its core technologies are based on microfluidics and mass cytometry, and enable the exploration and analysis of individual cells, as well as the industrial application of genomics.
Fluidigm – single-cell analysis
The Fluidigm microfluidic technology supports genomics-based applications such as single-cell gene expression, high-throughput SNP genotyping, protein expression analysis, digital PCR, mutant detection and more. Additionally, two of the company’s instruments have proven to be workhorses within the life science industry: the Biomark HD and C1 systems. Originally introduced in 2006 and updated in 2011, Biomark HD stands alone in the world of analytical instrumentation as a multiapplication platform without compromise, providing high quality results for every experimental approach. Since its debut in 2012, the C1 system has been revolutionizing single-cell research by enabling researchers to rapidly and reliably isolate, process and profile individual cells for genomic analysis.
Furthermore, the Fluidigm CyTOF mass cytometry systems use a novel technological approach to enable single-cell researchers to dissect intracellular networks. Most biochemistry and molecular biology knowledge assumes that the average behavior of cells in a population reflects how all cells in the populations behave. However, this assumption doesn’t appear valid when studying biological systems. Researchers are finding that stochastic fluctuations in gene or protein expression by individual cells in an otherwise identical group can lead to major differences in their behavior. Mass cytometry replaces the fluorophores used in traditional flow cytometry with stable, highly quantitative metal tags that are attached to specific antibodies and quantified using high-resolution mass spectrometry. CyTOF uses stable isotopes not normally found in biological systems to label antibodies and detect and quantify more than 100 different parameters per cell.
Fluidigm is a biotech company headquartered in San Francisco (USA). Management Team is composed by Gajus Worthington, Vikram Jog, Robert Jones, Fred Walder, Dominique Remy-Renou, William Smith, Grace Yow and Steven McPhail.
More aboiut Fluidigm : www.fluidigm.com